7607-41-2

Basic information

• Product Name: Benzamide, 4-nitro-N-[4-(trifluoromethyl)phenyl]-
• CAS NO: 7607-41-2
• Molecular Formula: C14H9F3N2O3
• Molecular Weight: 310.232
• Mol File: 7607-41-2.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Benzamide, 4-nitro-N-[4-(trifluoromethyl)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 4-nitro-N-[4-(trifluoromethyl)phenyl]-(7607-41-2)
• EPA Substance Registry System: Benzamide, 4-nitro-N-[4-(trifluoromethyl)phenyl]-(7607-41-2)

Safety Data

• Hazardous Substances Data: 7607-41-2(Hazardous Substances Data)

Upstream product

• 455-14-1 4-trifluoromethylphenylamine 
• 62-23-7 4-nitro-benzoic acid 
• 122-04-3 4-nitro-benzoyl chloride 

Downstream Products

• 221524-47-6 4-[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]aniline 
• 877603-41-3 2-(4-nitrophenyl)-6-trifluoromethyl-benzothiazole 
• 1621377-99-8 4-nitro-N-(4-(trifluoromethyl)phenyl)benzimidoyl chloride 
• 1621377-73-8 7-(trifluoromethyl)-3-(4-nitrophenyl)-1-phenyl-1,2-dihydrobenzo[1,2,4]triazin-2-yl 
• 1621377-87-4 N'-phenyl-N-[4-(trifluoromethyl)phenyl]-4-nitrobenzenecarbohydrazonamide 
• 1621378-28-6 7-(trifluoromethyl)-3-(4-(hexylamino)phenyl)-1-phenyl-1,2-dihydrobenzo[1,2,4]triazin-2-yl 
• 1621378-27-5 7-(trifluoromethyl)-3-(4-(N-BOC-pyrrolidine-2-carboxamido)phenyl)-1-phenyl-1,2-dihydrobenzo[1,2,4]triazin-2-yl 
• 1621378-26-4 7-(trifluoromethyl)-3-(4-aminophenyl)-1-phenyl-1,2-dihydrobenzo[1,2,4]triazin-2-yl 
• 90234-12-1 4-(Propane-2-sulfonylamino)-N-(4-trifluoromethyl-phenyl)-benzamide 
• 1034681-37-2 4-nitro-N-(4-(trifluoromethyl)phenyl)benzothioamide 
• 1257095-87-6 C₂₈H₁₆F₆N₄O₄S₂ 

Relevant articles and documents

Design, synthesis and antimetastatic evaluation of 1-benzothiazolylphenylbenzotriazoles for photodynamic therapy in oral cancer cells

We have designed and synthesized a new series of 1-benzothiazolylphenylbenzotriazoles 9a-p and studied their antimetastatic mechanism involved in photosensitive effects induced by UVA in oral cancer cell Ca9-22. Our results revealed that the compounds plus UVA significantly suppressed migration and invasion, as detected by wound healing assay and Boyden chamber assay. Quantitative RT-PCR assay indicated that compound 9i plus UVA induced an antimetastatic effect through up-regulation of syndecan-1 and TIMP-3 and down-regulation of heparanase, MMP-2 and MMP-9 mRNA expressions. Western blot analysis showed that Ca9-22 treated with 9i plus UVA resulted in decreased levels of p-EGFR and p-ERK, MMP-2 and MMP-9, and an increased level of TIMP-3. These results are the first to report the function of UVA-activated 1-benzothiazolylphenylbenzotriazoles in tumor metastasis and their underlying molecular mechanism, and thus suggest that compound 9i plus PDT may serve as a potential ancillary modality for the treatment of oral cancer.

Synthesis of 2-(4-aminophenyl) benzothiazole derivatives and use thereof

The present invention provides a method of preparing a compound of formula 6 comprising: (a) reacting a compound of formula 1 with a compound of formula 2 to form a compound of formula 3 wherein X of formula 2 is Cl or OH; (b) treating the compound formula 3 with Lawesson's reagent to form a compound of formula 4 (c) reacting a compound of formula 4 with potassium ferricyanide to produce a compound of formula 5 and (d) performing catalytic reduction of nitro group of the compound of formula 5 with palladium on charcoal to generate the compound of formula 6, wherein R1 of formulae 1-6 is H, C1-10 alkyl, C1-10 alkoxy or C1-10 haloalkyl, and R2 of formulae 1-6 is H or C1-10 alkyl. The present invention also provides a photodynamic therapy to a patient having at least one tumor comprising the steps of: administering a compound of formula 6 (wherein R1 and R2 are defined as the above) in a pharmaceutically acceptable carrier to the patient; waiting for a sufficient time to allow the administered compound to be taken up by a target tissue having the at least one tumor; and irradiating a region of the patient containing the target tissue; wherein growth of the tumor is inhibited.

Synthesis, and biological evaluation of 2-(4-aminophenyl)benzothiazole derivatives as photosensitizing agents

Photodynamic therapy (PDT) employing exogenous photosensitizers is currently being approved for treatment of basal cell carcinoma (BCC). 2-(4-Aminophenyl)benzothiazoles (6) consist of chromophoric structure and absorb light in the UVA (315-400 nm). These results encouraged us to design and synthesize a diversity of 2-phenylbenzothiazoles (6). Studies on the apoptotic mechanism involved in photosensitive effects induced by UVA-activated 6 in BCC cells are carried out in the present article. 6-UVA-treated cells displayed several features of apoptosis, including an increase in the sub-G1 population, a significantly increased annexin V binding, and activation of caspase-3. 6-UVA induced a decrease in mitochondrial membrane potential (Δψ mt) and ATP via enhanced ROS generation and promoted phosphorylation of extracellular signal-regulated kinase (ERK) and p38 MAPK expression. These results suggest that 6-UVA elicits photosensitive effects in mitochondria processes which involve ERK and p38 activation, and ultimately lead to BCC cell apoptosis.